Bharat Immunological & Biological Corporation Ltd Financial Ratios
BIBCL · Healthcare · Current price ₹15.3
P/E ratio
-3.8x
P/B ratio
-2.1x
ROE
-19.4%
ROCE
-9.0%
Debt / Equity
0.80
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | -3.8x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | -2.1x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | -19.4% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | -9.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.80 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Bharat Immunological & Biological Corporation Ltd's latest numbers.
Bharat Immunological & Biological Corporation Ltd profitability
Bharat Immunological & Biological Corporation Ltd generates a return on equity of -19.4% and a return on capital employed of -9.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.80 and a P/E of -3.8x, Bharat Immunological & Biological Corporation Ltd is moderately leveraged. Our overall business-quality score for the company is 2.7 / 10.
Understand the ratios
More on Bharat Immunological & Biological Corporation Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.